IVISbrite™ Staphylococcus aureus Xen29 bioluminescent bacteria was derived from a parental strain from the American Type Culture Collection (ATCC), used under license. For in vitro or in vivo imaging applications, IVISbrite S. aureus-Xen29 possesses a stable copy of the Photorhabdus luminescens lux operon on the bacterial chromosome.
For research use only. Not for use in diagnostic procedures.
false falsePlease enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Infectious disease is a perennially important area for both life science research and drug discovery. Some of the first applications of IVIS® imaging technology were in tracking infections and monitoring host responses, and these applications are still at the forefront of research.
Our bioluminescent infectious disease light-producing microorganisms have been developed to mimic both acute and chronic standard infection protocols presently used by researchers.
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vitro:
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vivo:
| Gram Positive Gram Negative | Gram positive |
|---|---|
| Luciferase Classification | Bacterial luciferase |
| Optical Imaging Classification | Bioluminescence Imaging |
| Product Brand Name | IVISbrite |
| Shipping Condition | Ambient |
| Therapeutic Area | Infectious Diseases |
| Unit Size | 1 agar plate |
Our comprehensive range of bioluminescent and fluorescent imaging reagents provide researchers with the necessary tools to better understand early disease-related biological changes, track disease progression, help guide the drug discovery process, and evaluate efficacy and safety of drug candida ...
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...
